Solute carrier family members control essential physiological functions and are tightly linked to human diseases. Solute carrier family 35 member F2 (SLC35F2) is aberrantly activated in several malignancies. However, the biological function and molecular mechanism of SLC35F2 in papillary thyroid carcinoma (PTC) are yet to be fully explored. Here, we showed that SLC35F2 was prominently upregulated in PTC tissues at both protein and mRNA expression level compared with matched adjacent normal tissues. Besides, the high expression of SLC35F2 was significantly associated with lymph node metastasis in patients with PTC. CRISPR/Cas9-mediated knockout of SLC35F2 attenuated the tumorigenic properties of PTC, including cell proliferation, migration and invasion and induced G1 phase arrest. In contrast, ectopic expression of SLC35F2 brought about aggressive malignant phenotypes of PTC cells. Moreover, SLC35F2 expedited the proliferation and migration of PTC cells by targeting transforming growth factor-b type I receptor (TGFBR1) and phosphorylation of apoptosis signal-regulating kinase 1 (p-ASK-1), thereby activating the mitogen-activated protein kinase signaling pathway. The malignant behaviors induced by overexpression of SLC35F2 could be abrogated by silencing of TGFBR1 using a specific inhibitor. We conducted the first study on SLC35F2 in thyroid cancer with the aim of elucidating the functional significance and molecular mechanism of SLC35F2. Our findings suggest that SLC35F2 exerts its oncogenic effect on PTC progression through the mitogen-activated protein kinase pathway, with dependence on activation of TGFBR-1 and apoptosis signal-regulating kinase 1.
Solute carrier family members control essential physiological functions and are tightly linked to human diseases. Solute carrier family 35 member F2 (SLC35F2) is aberrantly activated in several malignancies. However, the biological function and molecular mechanism of SLC35F2 in papillary thyroid carcinoma (PTC) are yet to be fully explored. Here, we showed that SLC35F2 was prominently upregulated in PTC tissues at both protein and mRNA expression level compared with matched adjacent normal tissues. Besides, the high expression of SLC35F2 was significantly associated with lymph node metastasis in patients with PTC. CRISPR/Cas9-mediated knockout of SLC35F2 attenuated the tumorigenic properties of PTC, including cell proliferation, migration and invasion and induced G1 phase arrest. In contrast, ectopic expression of SLC35F2 brought about aggressive malignant phenotypes of PTC cells. Moreover, SLC35F2 expedited the proliferation and migration of PTC cells by targeting transforming growth factor-b type I receptor (TGFBR1) and phosphorylation of apoptosis signal-regulating kinase 1 (p-ASK-1), thereby activating the mitogen-activated protein kinase signaling pathway. The malignant behaviors induced by overexpression of SLC35F2 could be abrogated by silencing of TGFBR1 using a specific inhibitor. We conducted the first study on SLC35F2 in thyroid cancer with the aim of elucidating the functional significance and molecular mechanism of SLC35F2. Our findings suggest that SLC35F2 exerts its oncogenic effect on PTC progression through the mitogen-activated protein kinase pathway, with dependence on activation of TGFBR-1 and apoptosis signal-regulating kinase 1.
| INTRODUCTION
The incidence of thyroid cancers has increased steadily in recent years. It accounts for 96% of endocrine system cancers and is one of the most rapidly increasing cancers in China. [1] [2] [3] Papillary thyroid carcinomas (PTC) are the predominant type of thyroid cancer and are slow growing and well-differentiated. Although a majority of PTC exhibit indolent behavior, a subset of PTC behave aggressively, with early-dissemination to local lymph nodes and oppression to organs, suggesting that some important determinants of clinical behavior exist. 4 Therefore, identification of molecular markers that could predict the metastatic potential of these lesions early on and new prevention strategies are urgently needed.
Solute carrier family 35 member F2 (SLC35F2) belongs to the solute carrier family, which is a superfamily of membrane-bound carriers involved in transportation of all kinds of substrates, such as metabolites, cofactors, vitamins, nutrients, ions and drugs. 5 The SLC gene superfamily controls essential physiological functions and its disturbance may result in diseases like malignancies. For example, Xu et al found that amplification of SLC12A5 plays a strong tumorigenic role and is associated with poor prognosis of patients with colorectal cancer. 6 SLC39A6 promotes aggressiveness of esophageal squamous carcinoma cells by increasing intracellular levels of zinc and activates phosphatidylinositol 3-kinase (PI3K) pathway. 7 SLC35, a group of nucleotide sugar transporters, currently comprises at least 31 homologous molecular species from SLC35A to SLC35G. SLC35A2 functions as a UDP-galactose transporter, whose substrate is required for galactosylation. In addition, SLC35D2 has been reported to translocate UDP-glucose into the Golgi as a substrate for heparan sulfate synthesis. 8 However, only one-third of the whole solute carrier family members have been studied in detail. Little is known about most of the members in the SLC35 family, and SLC35F2 is one of them. The expression of SLC35F2 was initially found in ataxia telangiectasia. 9 Subsequently, Nishimura et al discovered that it had the highest expression level in human adult salivary glands (detected by RT-PCR). 10 Bu et al report that SLC35F2 was highly expressed in non-small cell lung cancer (NSCLC) tissues, was associated with the pathological stage and had prognostic value in NSCLC. 11 Nyquist et al found that SLC35F2 expression was linked to intratumor androgen levels and was regulated by the androgen receptor axis signaling in prostate cancer. 12 Recently, a study verified SLC35F2 as a cargo of anti-cancer drug YM155 and determined that lack of SLC35F2 was capable of conferring drug resistance. 13 Therefore, SLC35F2
could be used as a clinical biomarker for YM155 susceptibility. 
| Cell proliferation and colony formation
Proliferation ability of thyroid cancer cells was measured using Cell
Counting Kit-8 reagent (CCK8, Dojindo, Japan). Approximately, Tumor volume was calculated with a caliper and evaluated using the formula: (length 9 width 2 )/2. Five weeks post-injection, the mice were killed and the tumors were weighed; IHC and HE staining were performed. 15 we found that SLC35F2 expression was significantly overexpressed in human PTC tissues ( Figure 1A ). To verify the robustness of data mining results, we first explored the expression of SLC35F2 in PTC (Table 1) . Among the 42 PTC cases, 29 (69.0%) patients were defined as the high group with this ratio above 2-fold and 13 (31.0%) patients were defined as the low group with the ratio below 2-fold. Strikingly, SLC35F2 expression was closely correlated with the presence of lymph node metastasis (P = .0109). Next, we used immunohistochemistry staining in another cohort containing 40 patients to verify the clinical relevance of SLC35F2 in PTC, consistent with prior findings, IHC analysis of paired PTC and adjacent normal tissues also confirmed its overexpression at the protein level (Figure 1E) . Moreover, patients with lymph node metastasis had higher SLC35F2 staining scores than those without lymph node metastasis ( Figure S1 ). Taken together, our results demonstrate that SLC35F2 is an oncoprotein, whose expression is closely associated with lymph node metastasis.
| Cell migration and invasion assay

| Statistical analysis
| Solute carrier family 35 member F2 is required for papillary thyroid carcinoma cell proliferation
To further investigate the biological function of SLC35F2 overexpression in PTC progression, BCPAP and KTC-1 cell lines that stably knock out or overexpress SLC35F2 were established. We used a lentiCRISPR v2 vector and designed sgRNA against exon 7 of SLC35F2.
As CRISPR-Cas9 knockout system causes indel mutation, the level of G1/S transition, we applied western blotting to investigate whether SLC35F2 exerts its oncogenic activity through modulation of certain cyclins and cyclin-dependent kinases. As shown in Figure 3E and F, the protein levels of CDK2, CDK4, CDK6, Cyclin D1 and 3.5 | Solute carrier family 35 member F2 promotes papillary thyroid carcinoma progression through activating transforming growth factor-b type I receptor/apoptosis signal-regulating kinase 1/ mitogen-activated protein kinase pathway So far, the related downstream pathway for SLC35F2 has not been reported. Therefore, we aimed to identify the potential pathways by which SLC35F2 contributes to the malignant phenotype of PTC cells. We performed Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis on the GSE3678 dataset using DAVID Bioinformatics Resources 6.7. 16 A list of genes that have strong co-expression correlation (Pearson r value >.7 or < À.7) with SLC35F2 were extracted from this dataset (Table S1 ). GO enrichment analysis showed that these genes were tightly associated with cell proliferation and intracellular signaling cascade, supporting the role of SLC35F2 in PTC development ( Figure 5A and Table S1 ).
Meanwhile, KEGG enrichment analysis demonstrated that the MAPK pathway is among the most significantly altered pathways ( Figure 5B and Table S1 ). Therefore, we assessed several critical cellular protein kinases in MAPK pathway. Interestingly, we discovered that suppression of SLC35F2 inhibited the phosphorylation of ERK1/2, p38
MAPK and JNK at protein levels. However, the total ERK1/2, p38 MAPK and JNK were almost unchanged ( Figure 5C ). The activity of phosphor-p38 MAPK, phosphor-JNK and phosphor-Erk1/2 is directly implicated in the progression of PTC. The phosphorylation status of these proteins represents the activation of MAPK pathway, which is a key molecular signaling pathway involved in thyroid cancer. Similarly, overexpression of SLC35F2 increased protein levels of phosphorylated ERK1/2, p38 MAPK and JNK, and vice versa ( Figure 5D ).
Meanwhile, we observed an increased p-ERK, p-p38 MAPK and p-JNK expression in PTC specimens compared with their normal counterparts ( Figure S3 ). To further clarify the mechanism by which SLC35F2 activates MAPK pathway, we noticed that transforming growth factor-b type I receptor (TGFBR1) and apoptosis signal-regulating kinase 1 (ASK-1), core members of the MAPK pathway, were emerged in the co-expression gene list (Table S1 ). According to the TCGA THCA dataset, the expression level of SLC35F2 was positively correlated with TGFBR1 (r = .7225, P < .0001, n = 513) and ASK-1 (r = .7006, P < .0001, n = 513) (Figure 5e ). TGFBR1, a receptor of for TGF-b ligand, was less studied in PTC. We analyzed the expression of TGFBR1 in our cohort and found that TGFBR1 was upregulated in PTC samples. The clinical relevance between SLC35F2 and TGFBR1 was also investigated and results showed that TGFBR1 expression is strongly linked to SLC35F2 (r = .6840, P < .0001) (Figure 5f ). We next tested whether SLC35F2 promotes PTC progres- 
| DISCUSSION
It is generally assumed that approximately 10% of all human genes are transporter-related, consistent with the biological significance of transporters, channels and pumps. 17 A previous study has reported that over 456 SLC transporters in 52 subfamilies constitute the SLC superfamily. 18 The SLC transporter family is one of the least studied groups of genes compared to other gene families of similar stature.
Technical barriers such as structural biology characterization and non-available high-quality antibodies of most of SLC impeded research in this area. Defining their endogenous natural substrates is especially challenging. 19 Genome-wide association studies revealed that approximately 190 different SLC had been found mutated in human disease, including PTC. Solute carrier family 5A (SLC5A), the sodium iodide symporter (NIS), mediates the transport of iodine anion (I À ) into thyroid follicular cells to facilitate thyroid hormone biosynthesis. 20 Gene polymorphism of SLC5A conferred the risk for differentiated thyroid cancer. 21 Hu et al found that the hypermethylation of SLC5A8 has been associated with advanced stage of tumors, multifocality and extrathyroidal invasion in PTC. 22 Besides, methylation of SLC5A8 is associated with the BRAF V600E mutation, which is the most frequent genetic event during the development of PTC. 23 In the current study, we present both in vitro and in vivo However, the underlying mechanism responsible for aberrant expression of SLC35F2 in PTC is still unknown. Epigenetic changes such as histone acetylation or methylation of its promoter might result in F I G U R E 3 Cyclin-dependent kinases and cyclins are involved in solute carrier family 35 member F2 (SLC35F2)-regulated cell cycle progression. A, Effects of SLC35F2 knockout on cell cycle by FACS. B, Cell cycle distribution showed that inhibition of SLC35F2 induced cell cycle arrest at G1 phase. C, Flow cytometry analysis of the cell cycle of SLC35F2 overexpression and empty vector control cells. D, Ectopic expression of SLC35F2 promoted G1/S phase transition and increased S-phase proportion. E, F, Protein levels of CDK2, CDK4, CDK6, Cyclin D1, Cyclin D3, p27 Kip1, p21 Waf1/Cip 1 and p18 INK4C were detected by western blotting in indicated PTC cells. G, Relative mRNA expression levels of some cell cycle related genes analyzed by qPCR in SLC35F2-KO group compared to control KTC-1 cells. Data were plotted relative to expression levels in control cells (*P < .05, **P < .01, ***P < .001) Accumulating evidence reveals that sustaining proliferative signaling through the deregulated cell cycle is an essential step during carcinogenesis. 24, 25 Cyclin-dependent kinase (CDK)-cyclin complexes have been described as the critical regulatory enzymes in the cell cycle. 26 CDK4 and CDK6 are the main interphase CDK, activated by cyclin D1, D2 and D3, and form CDK4/6-cyclin D complexes, orchestrating the advance of the cell cycle entry and progression through G1 phase. 27 In contrast, CDK inhibitors (CKI), such as the cip/Kip family proteins, p21 Waf/Cip1 and p27 Kip1, bind to and inhibit the activity of the above CDK-cyclin complexes, which are participated in the negative control of cell cycle progression. 28 Numerous CDK inhibitors were expected to be an effective strategy because many tumorigenic events eventually drive proliferation by subverting CDK4 or CDK6 complexes in the G1 phase of the cell cycle. 29, 30 Therefore, clarifying the mechanism concerning the dysregulation of cell cycle regulator will be of great importance. Sun et al previously demonstrated a new miR-144/E2F8/Cyclin D1 regulatory axis controlling PTC development. 31 Here, we proved that 
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